echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Xinda/Lilly's cooperation on Dabershu has been extended through the U.S. HSR Act waiting period.

    Xinda/Lilly's cooperation on Dabershu has been extended through the U.S. HSR Act waiting period.

    • Last Update: 2020-10-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Thyme Biopharmaceuticals (HKEx: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as cancer, metabolic diseases and autoimmunity, announced on October 7th that it would The company's expanded global strategic partnership with Lilly Pharmaceuticals on August 18th to expand the Dabershu ® (Syndilly monoantigen injection) has passed the waiting period for the Hart-Scott-Rodino ("HSR") Act in the United States.
    all the conditions for this cooperation agreement are in place and the transaction is in force.
    and Lilly Pharmaceuticals will make the necessary transfer of authorization documents in accordance with the terms of the partnership, and Lilly Pharmaceuticals will make a $200 million down payment to Xinda Bio for the partnership.
    (® Single Anti-Injection) is an innovative, international-quality biologic drug developed in China by Xinda Biopharmaceuticals and Lilly Pharmaceuticals.
    the first adaptation approved was relapsed/resuscipable classic Hodgkin's lymphoma, which was selected in the 2019 edition of the China Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of lymphoma.
    the 2019 Health Care National ®, Dabershu ® is the only PD-1 inhibitor that enters the national health care system.
    In April 2020, NMPA officially accepted applications for new adaptations to Dabershu® (Syndili monoantigen injections) combined Libitai ® (injected with Pymoxyse di sodium) and platinum chemotherapy for the first-line treatment of non-squamous non-small cell lung cancer® Injection) THE ORIENT-2 study of single-drug second-line treatment of advanced/metastatic esophageal squamous cancer reached the end of the main study, and in August 2020, NMPA officially accepted applications for new adaptations to Dabershu® (Cindili monoanti-injection) joint health options ® (injection with gisithamin) and platinum chemotherapy for first-line treatment of squamous non-small cell lung cancer.
    September 2020, The multicenter Phase III clinical study (ORIENT-32) of Dabershu ® (Cindili monoantigen injection) and the same ® (Beval pearl monoantigen injection) for the first-line treatment of advanced liver cancer reached the end of the phase III clinical study (ORIENT-32).
    Dabershu® (Syndili monoantigen injection) is a human immunoglobulin G4 (IgG4) monoclonal antibody that specificly binds to PD-1 molecules on the surface of T cells, thereby blocking the PD-1/programmed death complex 1 (Programmed Death-Ligand 1), which causes immune tolerance to tumors. PD-L1) path, reactivates the anti-tumor activity of lymphocytes, thus achieving the goal of treating tumors.
    more than two dozen clinical studies, more than 10 of which are registered clinical trials, are currently under way to assess the anti-tumor effects of Syndication on a wide range of solid and blood tumors.
    Xinda Bio is also conducting clinical research on Xindili monoantigen injections worldwide.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.